What is GeneOne Life Science, Inc.'s (011000.KS) StockRank?

MoatMap's StockRank for GeneOne Life Science, Inc. (011000.KS) is 1/100, with a Strong Sell signal. This is a composite score combining Quality (15), Value (41), and Momentum (10) factor ranks across MoatMap's 20,000+ stock universe.

Does GeneOne Life Science, Inc. have an economic moat?

GeneOne Life Science, Inc. (011000.KS) has a Quality factor score of 15/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is GeneOne Life Science, Inc. a buy, hold, or sell?

MoatMap's current signal for GeneOne Life Science, Inc. (011000.KS) is Strong Sell, based on a StockRank of 1/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is GeneOne Life Science, Inc. in?

GeneOne Life Science, Inc. (011000.KS) operates in the Healthcare sector, specifically the Biotechnology industry (South Korea).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

011000.KS

STRONG SELLREMOVE

GeneOne Life Science, Inc. · Healthcare · South Korea · $68M · Avg Vol: $6M/d

StockRank

P/E (TTM)

—

ROE

-71.2%

D/E

0.7x

Dividend %

—

Director Trades · 180d

None in 180d →

Buybacks · 180d

None in 180d →

AI CONVICTION THESIS

GeneOne Life Science is a clinical-stage gene therapy developer and small-scale CDMO. It lacks the scale, high utilization, and regulatory moats of the large-scale biologics CDMOs that we target in our CDMO Pricing Power theme, and is structurally unprofitable.

COMPANY DESCRIPTION

GeneOne Life Science, Inc. develops gene therapies, DNA vaccines, and small molecule drugs, while providing contract development and manufacturing (CDMO) services. The company's competitive moat is its specialized plasmid DNA manufacturing facility in the US (VGXI), serving global biopharma clients. It is a clinical-stage biotechnology company combining innovative drug development with a revenue-generating CDMO business model.

FINANCIAL SUMMARY (USD)

Year	2022	2023	2024	2025	CAGR
Revenue	32M	26M	24M	15M	-22.1%
EPS	-0.32	-0.66	-0.40	-0.41	—
Shares	78M	78M	80M	85M	+9.6%
Debt	13M	11M	18M	22M	18.8%
Equity	119M	73M	56M	27M	-39.1%
Op CF	-16M	-14M	-11M	-11M	—
Inv CF	5M	17M	-2M	-506,787	—
Fin CF	5M	-5M	7M	11M	—

PRICE (1M)+4.1%

SMA 50SMA 200

$0.55

RSI (14)

25.6

52W High

$2.01

From 52W High

0.3%

SCORE BREAKDOWN

Quality

ROIC

-71.6%8.2

ROE

-71.2%11.5

GP/Assets

-10.9%6.5

Op. Margin

-90.8%17.4

FCF/Assets

-0.1%50.2

Piotroski

—7.2

Int. Cover

-9.1x25.5

D/E Ratio

0.67x24.8

Current Ratio

0.46x2.0

Value

P/E (TTM)

—N/A

EV/EBITDA

-4.8x72.8

P/FCF

—N/A

P/B

1.9x57.1

P/S

4.8x42.3

Div Yield

—N/A

Momentum

52W High %

28%4.5

RS 6M

-179%0.4

SMA 50/200

0.61x2.3

EPS Rev 4W

—N/A

EPS Rev 12W

—N/A

EPS Improve

—N/A

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$68M

P/E (Forward)

—

Gross Margin

-78.3%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 011000.KS are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
011000.KS	GeneOne Life Science, Inc.(you)	$68M	1	STRONG SELL
456070.KQ	ENCell	$63M	5	STRONG SELL
203400.KQ	ABION Inc.	$54M	2	STRONG SELL
323990.KQ	Vaxcell-Bio Therapeutics Co., Ltd.	$88M	2	STRONG SELL
166480.KQ	CORESTEMCHEMON Inc.	$69M	9	STRONG SELL
235980.KQ	MedPacto, Inc.	$80M	6	STRONG SELL
389030.KQ	GENINUS Inc.	$74M	14	STRONG SELL
095700.KQ	Genexine, Inc.	$111M	7	STRONG SELL
338840.KQ	Y-Biologics	$136M	3	STRONG SELL
321550.KQ	TiumBio Co., Ltd.	$127M	7	STRONG SELL

Peer medians: ROE -1.1% · P/E 17.7x · Gross margin 43.6%

GeneOne Life Science, Inc. (011000.KS) — Stock Score Summary

GeneOne Life Science, Inc. (011000.KS) has a MoatMap StockRank of 1/100 based on Quality (15/100), Value (41/100), and Momentum (10/100) factor scores. The current signal is STRONG SELL. GeneOne Life Science is a clinical-stage gene therapy developer and small-scale CDMO. It lacks the scale, high utilization, and regulatory moats of the large-scale biologics CDMOs that we target in our CDMO Pricing Power theme, and is structurally unprofitable.

Key Financial Metrics

Price	$0.55
Market Cap	$68M
Price/Book	1.91
Return on Equity	-71.2%
Return on Invested Capital	-71.6%
Debt/Equity	66.76
Gross Margin	-78.3%
Operating Margin	-90.8%
Revenue Growth	-69.6%
Free Cash Flow	$-33.04

GeneOne Life Science, Inc. operates in the Biotechnology industry, part of the Healthcare sector (South Korea).

Frequently Asked Questions

What is GeneOne Life Science, Inc.’s (011000.KS) StockRank?: MoatMap’s StockRank for GeneOne Life Science, Inc. (011000.KS) is 1/100, with a Strong Sell signal. It is a composite of Quality (15), Value (41), and Momentum (10) factor ranks across MoatMap’s 20,000+ stock universe.
Does GeneOne Life Science, Inc. have an economic moat?: GeneOne Life Science, Inc. (011000.KS) has a Quality factor score of 15/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is GeneOne Life Science, Inc. a buy, hold, or sell?: MoatMap’s current signal for GeneOne Life Science, Inc. (011000.KS) is Strong Sell, based on a StockRank of 1/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is GeneOne Life Science, Inc. in?: GeneOne Life Science, Inc. (011000.KS) operates in the Healthcare sector, specifically the Biotechnology industry (South Korea).